Summary: New research uncovers a previously unknown genetic connection between increased platelet distribution width and higher risk of developing Parkinson’s disease.
Source: Mater
A Mater Research study has uncovered a novel genetic relationship between platelets and Parkinson’s disease, with the findings published in Cell Genomics.
The investigation, led by Associate Professor Jake Gratten and Dr. Yuanhao Yang from Mater Research and The University of Queensland, analyzed large-scale genetic data to clarify cause-and-effect relationships between blood cell measures and a range of common neurological and psychiatric disorders.
Dr. Yang, the lead author, explained that the study was prompted by previous observations linking various blood measurements with risks for conditions such as stroke, multiple sclerosis and depression. Those earlier associations raised the question of whether shared genetics underlie these relationships and whether any observed connections might reflect causal pathways.
By systematically integrating genome-wide association study (GWAS) summary statistics for 29 blood cell traits and 11 neurological and psychiatric disorders, the team mapped genetic correlations and performed Mendelian randomization analyses. The goal was to determine which correlations reflect shared genetic architecture and which might indicate causal effects that could be exploited for early detection, prevention or treatment.
One of the most significant and novel findings was evidence that increased platelet distribution width (PDW) has a causal effect on the risk of Parkinson’s disease. Platelet distribution width describes variation in platelet size and is routinely measured in standard blood tests. The study’s Mendelian randomization results suggest that higher PDW may not be merely an associated biomarker but could play a role in the biological processes that increase susceptibility to Parkinson’s disease.
Beyond this specific causal link, the researchers detected widespread genetic overlap between blood cell traits and the set of brain disorders examined. They identified multiple genes and regulatory elements that are shared across particular blood traits and neurological or psychiatric conditions. Notably, some of these genes are known drug targets for other diseases, pointing to opportunities for drug repurposing and therapeutic development focused on common brain disorders.
Senior author Associate Professor Gratten emphasized the practical implications: these results create a foundation for further research aimed at improving prevention, prognosis and treatment of common neurological diseases and psychiatric disorders. By clarifying which blood-based measures are genetically linked to brain disorders, the work highlights candidate biomarkers that could be validated in clinical studies and, ultimately, used to refine screening or risk prediction strategies.
About this Parkinson’s disease research news
Author: Press Office
Source: Mater
Contact: Press Office – Mater
Image: The image is in the public domain
Original Research: Open access.
Title: The shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders by Yuanhao Yang et al., published in Cell Genomics.
Abstract
The shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders
Phenotypic associations have been reported between blood cell traits (BCTs) and a spectrum of neurological and psychiatric disorders (NPDs), yet it has often been unclear whether those epidemiological links reflect shared genetic causes or causal relationships. To address this, the study examined genetic correlations and applied Mendelian randomization methods across 11 NPDs and 29 BCTs using genome-wide association study summary statistics.
The analysis identified significant genetic correlations for several BCT–NPD pairs, consistent with prior phenotypic observations. Crucially, the researchers discovered a previously unreported causal effect: increased platelet distribution width appears to raise susceptibility to Parkinson’s disease. In addition, the study pinpointed multiple functional genes and regulatory elements that contribute to specific BCT–NPD associations; some of these genes are already the targets of existing drugs.
These results deepen our understanding of the shared genetic landscape connecting blood cell measures with neurological and psychiatric conditions. They provide a robust platform for future investigations into biomarkers, drug repurposing and therapeutic strategies aimed at improving prognosis, early detection and treatment of common brain disorders.